TUMOR ANGIOGENESIS IS AN INDEPENDENT PROGNOSTIC INDICATOR IN PRIMARY BREAST-CARCINOMA

TUMOR ANGIOGENESIS IS AN INDEPENDENT PROGNOSTIC INDICATOR IN PRIMARY BREAST-CARCINOMA
复制标题

DOI:
10.1002/ijc.2910550305
复制
发表时间:
1993-09-30
影响因子:
6.4
通讯作者:
TOMINAGA, T
TOMINAGA, T
中科院分区:
医学1区
文献类型:
--
作者:
TOI, M;KASHITANI, J;TOMINAGA, T

文献摘要

被引文献

相似文献

在125例原发性乳腺癌患者中研究了肿瘤血管生成的临床重要性,特别是其作为预后指标的意义。通过免疫细胞化学法对第八因子抗原进行染色,以血管密度来评估新生血管的等级。术后调查表明,血管密度是无复发生存率的统计学显著预测因子(中位随访期:62个月)。在新生血管最活跃的区域中,每200 x视野中因子VIII抗原阳性细胞计数超过100的患者的预后显著差于计数小于100的患者。血管密度的预后价值也通过另一种评价方法得到证实,该方法使用CD-31免疫细胞化学染色,CD-31是一种血小板/内皮细胞粘附分子。CD-31阳性细胞计数较高的患者和计数较低的患者之间无复发生存率存在显著差异。按淋巴结状态分层的分类分析显示,在淋巴结阴性和淋巴结阳性患者中,血管密度是一个重要的预后指标。多因素分析表明,血管密度是乳腺癌患者独立的预后指标。(C)1993 Wiley-Liss,Inc.
Clinical importance of tumor angiogenesis, especially its significance as a prognostic indicator, was examined in 125 primary breast-cancer patients. The grade of neovascularization was assessed by the vessel density which was obtained by immunocytochemical staining for factor VIII antigen. Post-operative survey demonstrated that the vessel density is a statistically significant predictor of relapse-free survival (median follow-up period: 62 months). Patients with over 100 counts of factor-VIII antigen-positive cells per 200 x field in the most active areas of neovascularization showed significantly poorer prognosis than those with less than 100 counts. The prognostic value of the vessel density was also confirmed by another evaluation method using immunocytochemical staining to CD-31 which is a platelet/endothelial cell adhesion molecule. A significant difference in relapse-free survival rate was shown between patients having higher counts of CD-31 positive cells and those having lower counts. Breakdown analysis stratified by nodal status showed that the vessel density was a significant prognostic indicator in node-negative and node-positive patients. Multivariate analysis indicated that the vessel density is an independent prognostic indicator in primary breast-cancer patients. (C) 1993 Wiley-Liss, Inc.